BELLEVUE, Wash. The specialty pharmacy company SCOLR Pharma has extended its research agreement with a global consumer products company to co-develop a new application of its CDT drug delivery technology.
Under the terms of the agreement, SCOLR will receive a research fee. If the program is successful, it is anticipated that the parties would enter a global license agreement to allow for application of SCOLR’s technology.
Stephen Turner, SCOLR’s vice president and chief technical officer, stated “This extension is a positive indication of the progress we are making with our co-development partner on a novel application of our CDT drug delivery technology. We remain optimistic that if successful, a branded consumer product incorporating our technology could begin commercialization by 2009.”
SCOLR recently entered a development and licensing agreement with Dr. Reddy, for a cardiopulmonary application of its CDT technology. The company also continues its collaboration with Biocryst to develop an oral application of Biocryst’s peramivir, an anti-viral compound currently in clinical trials as potential intramuscular and intervenous treatments for seasonal and life-threatening influenza.